The NLRP1 inflammasome in human skin and beyond by Fenini, Gabriele et al.








The NLRP1 inflammasome in human skin and beyond
Fenini, Gabriele ; Karakaya, Tugay ; Hennig, Paulina ; Di Filippo, Michela ; Beer, Hans-Dietmar
Abstract: Inflammasomes represent a group of protein complexes that contribute to host defense against
pathogens and repair processes upon the induction of inflammation. However, aberrant and chronic
inflammasome activation underlies the pathology of numerous common inflammatory diseases. Inflam-
masome assembly causes activation of the protease caspase-1 which in turn activates proinflammatory
cytokines and induces a lytic type of cell death termed pyroptosis. Although NLRP1 (NACHT, leucine-
rich repeat and pyrin domain containing 1) was the first inflammasome sensor, described almost 20 years
ago, the molecular mechanisms underlying its activation and the resulting downstream events are in-
completely understood. This is partially a consequence of the poor conservation of the NLRP1 pathway
between human and mice. Moreover, recent evidence demonstrates a complex and multi-stage mecha-
nism of NLRP1 inflammasome activation. In contrast to other inflammasome sensors, NLRP1 possesses
protease activity required for proteolytic self-cleavage and activation mediated by the function-to-find
domain (FIIND). CARD8 is a second FIIND protein and is expressed in humans but not in mice. In
immune cells and AML (acute myeloid leukemia) cells, the anti-cancer drug talabostat induces CARD8
activation and causes caspase-1-dependent pyroptosis. In contrast, in human keratinocytes talabostat
induces NLRP1 activation and massive proinflammatory cytokine activation. NLRP1 is regarded as the
principal inflammasome sensor in human keratinocytes and UVB radiation induces its activation, which
is believed to underlie the induction of sunburn. Moreover, gain-of-function mutations of NLRP1 cause
inflammatory skin syndromes and a predisposition for the development of skin cancer. SNPs (single
nucleotide polymorphisms) of NLRP1 are associated with several (auto)inflammatory diseases with a
major skin phenotype, such as psoriasis or vitiligo. Here, we summarize knowledge about NLRP1 with
emphasis on its role in human keratinocytes and skin. Due to its accessibility, pharmacological targeting
of NLRP1 activation in epidermal keratinocytes represents a promising strategy for the treatment of the
numerous patients suffering from NLRP1-dependent inflammatory skin conditions and cancer.
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Abstract: Inflammasomes represent a group of protein complexes that contribute to host defense
against pathogens and repair processes upon the induction of inflammation. However, aberrant and
chronic inflammasome activation underlies the pathology of numerous common inflammatory
diseases. Inflammasome assembly causes activation of the protease caspase-1 which in turn
activates proinflammatory cytokines and induces a lytic type of cell death termed pyroptosis.
Although NLRP1 (NACHT, leucine-rich repeat and pyrin domain containing 1) was the first
inflammasome sensor, described almost 20 years ago, the molecular mechanisms underlying its
activation and the resulting downstream events are incompletely understood. This is partially a
consequence of the poor conservation of the NLRP1 pathway between human and mice. Moreover,
recent evidence demonstrates a complex and multi-stage mechanism of NLRP1 inflammasome
activation. In contrast to other inflammasome sensors, NLRP1 possesses protease activity required
for proteolytic self-cleavage and activation mediated by the function-to-find domain (FIIND). CARD8
is a second FIIND protein and is expressed in humans but not in mice. In immune cells and AML
(acute myeloid leukemia) cells, the anti-cancer drug talabostat induces CARD8 activation and causes
caspase-1-dependent pyroptosis. In contrast, in human keratinocytes talabostat induces NLRP1
activation and massive proinflammatory cytokine activation. NLRP1 is regarded as the principal
inflammasome sensor in human keratinocytes and UVB radiation induces its activation, which is
believed to underlie the induction of sunburn. Moreover, gain-of-function mutations of NLRP1 cause
inflammatory skin syndromes and a predisposition for the development of skin cancer. SNPs (single
nucleotide polymorphisms) of NLRP1 are associated with several (auto)inflammatory diseases with a
major skin phenotype, such as psoriasis or vitiligo. Here, we summarize knowledge about NLRP1
with emphasis on its role in human keratinocytes and skin. Due to its accessibility, pharmacological
targeting of NLRP1 activation in epidermal keratinocytes represents a promising strategy for the
treatment of the numerous patients suffering from NLRP1-dependent inflammatory skin conditions
and cancer.
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1. Introduction
Skin represents the essential outer barrier of the human body and is in permanent contact with
the environment [1]. Its outermost compartment, the epidermis, consists of several layers of densely
packed cells, named keratinocytes, in defined stages of differentiation. The epidermis is a constantly
renewing tissue. Under homeostatic conditions, proliferation of keratinocytes is restricted to the
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innermost layer. These basal keratinocytes migrate outwards, differentiate and change their expression
profile, finally die and fuse to a structure, termed cornified envelope, which is particularly important
for the barrier function of the epidermis. In contrast to the underlying dermis, a connective tissue,
the epidermis contains only few immune cells [2,3]. Keratinocytes of the epidermis do not only form
the outer structural barrier, but express in a constitutive or inducible manner also molecules, peptides
and proteins, which are actively involved in anti-bacterial and anti-viral defense as well as in immune
responses, such as anti-microbial peptides or proinflammatory cytokines [3].
In the skin, but also in other tissues, the detection of stress factors can mount a highly complex
response, termed inflammation [4]. Inflammation is an essential and beneficial process required to
combat pathogenic invaders or to induce tissue repair after injury. However, when chronic or/and
out of control, inflammation becomes detrimental and causes or contributes to numerous widespread
(inflammatory) diseases. Therefore, the interest in understanding the molecular events regulating
inflammation is very high and these efforts can potentially result in the development of novel strategies
for the pharmacological targeting of inflammation. Chronic inflammation constitutes also a hallmark in
cancer development [5]. By creating a “smoldering” inflammatory environment, innate and adaptive
immune cells can trigger the development and growth of tumors as well as invasion and metastasis [6].
In contrast, via anti-tumor cytotoxic T cell activity and cytokine-mediated lysis of tumor cells, adaptive
immune cells inhibit the growth of tumors, and activation of the immune system by immunotherapy
represents a successful anti-cancer strategy. Therefore, inflammation represents a double-edged sword
for carcinogenesis, able to support this process at all stages and at the same time be capable of efficient
suppression [6].
2. Inflammasomes
Upon detection of different stress factors, termed pathogen- or damage/danger-associated
molecular patterns (PAMPs, DAMPs), cytoplasmic NOD-like receptors (NLRs) form oligomers.
These complexes, termed inflammasomes, cause a series of downstream events and ultimately inducing
inflammation [7,8]. In 2002, the group of Jürg Tschopp described the activation of NLRP1, the first
inflammasome sensor [9]. Later, the NLRC4 [10], NLRP3 [11,12] as well as the AIM2 (absent in
melanoma 2) [13,14] and pyrin [15] inflammasomes were discovered. Direct binding of cytoplasmic
DNA, which may derive from pathogens or dying cells, activates the AIM2 inflammasome and
contributes to defense against bacteria and viruses [13,14]. In contrast, the molecular mechanisms
underlying NLRP3 activation are not well understood. NLRP3 is activated by many different
stress factors, which cannot all bind to NLRP3 and cause its activation, due to their chemical and
structural diversity. Therefore, indirect mechanisms of NLRP3 activation are discussed [16]. As it
is believed that NLRP3 activation contributes to common inflammatory diseases but is dispensable
for immunity against pathogens, therapeutic targeting and inhibition of NLRP3 is a major issue for
pharmacological treatment of the many patients suffering from NLRP3-associated diseases [17,18].
Most inflammasome sensors contain a pyrin domain [19–21] which is, like CARD (caspase activation
and recruitment domain), characterized by a death domain fold, allowing homotypic protein-protein
interactions [22]. After stress factor-induced activation and oligomerization of NLRs, they bind to
the pyrin domain of the adaptor protein ASC (apoptosis-associated speck-like protein containing a
CARD) via homotypic interaction inducing the formation of large multimers, termed ASC specks [23].
Via its CARD, ASC interacts in a homotypic manner with (pro-)caspase-1, resulting in dimerization
of the protease followed by proteolytic self-activation. Caspase-1 represents the effector molecule
of inflammasomes and belongs to a family of cysteine proteases, which regulate cell death and
apoptosis [22]. The proinflammatory cytokines proIL(interleukin)-1β and -18 are substrates of
caspase-1 [24]. Active caspase-1 cleaves and thereby activates proIL-1β and -18 and the secretion
of these active cytokines induces inflammation. Interestingly, IL-1β and -18 as well as several other
proteins with extracellular functions, particularly during inflammation, lack a signal sequence for their
secretion by the canonical endoplasmic reticulum/Golgi-dependent pathway. These proteins leave the
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cell via regulated or passive mechanisms collectively termed unconventional protein secretion [25,26].
Interestingly, caspase-1 activity is not only required for activation of proIL-1β and -18 but also for their
secretion and release [27]. Caspase-1 cleaves gasdermin D and the resulting aminoterminal fragment
inserts into the extracellular membrane upon oligomerization [28]. The resulting pores allow release
of IL-1β, IL-18 and other cytoplasmic proteins, as well as the entrance of water, causing swelling
and finally bursting of the cells [28–32]. However, living cells are also able to secrete IL-1β with low
levels of gasdermin D activation [33–39]. To summarize, inflammasomes represent a group of protein
complexes, which induce inflammation upon sensing different types of stress factors.
3. The Molecular Mechanisms Underlying NLRP1 Activation
Human NLRP1 is with 1473 amino acids the largest inflammasome sensor [40]. It possesses an
aminoterminal pyrin domain, a NACHT domain, LRRs (leucine-rich repeats), FIIND (function-to-find
domain), and a carboxyterminal CARD (Figure 1a). In contrast to NLRP3, AIM2, pyrin and some
poorly characterized inflammasome sensors [40], the carboxyterminal CARD of NLRP1 is part of the
effector domain, which induces ASC speck formation [41,42]. The function of the carboxyterminal
pyrin domain, which is missing in murine NLRP1, is not clear but seems to be required for keeping





Figure 1. Isoforms of human NLRP1 and CARD8. (a) Full-length NLRP1 consists of five domains,
an aminoterminal pyrin domain (PYD), a NACHT domain (NACHT), a leucine-rich repeats domain
(LRRs), a function-to-find domain (FIIND), and a carboxyterminal caspase activation and recruitment
domain (CARD). Self-processing occurs at S1213 in the SF/S motif of the FIIND. NLRP1 is encoded
by up to 17 exons. Exon 8 is missing in isoform 4 (NACδ) and isoform 3 (NACγ) whereas exon 14
is missing in isoform 2 (DEFCAP-S, NACα) and isoform 3 (NACγ). Isoform 5 and 7 have 4 amino
acids (GKSH) insertion after A1044 or A78, respectively. Selected NLRP1 mutations in human disease
with skin involvement are depicted (for more information refer to Table 1). (b) CARD8 contains two
domains, a FIIND and a CARD, with a variable aminoterminus and is encoded by up to 11 exons. T54
isoform misses exon 2 whereas isoform 1 (T48), isoform 2 (short), and T51 have alternative splicing
replacing exons 1-3. CARD8 short, long and T47 have a deletion at A153 and A148, respectively.
The SNP rs2043211 causes mutations in T60, T54, and T48, introducing in the latter a stop codon.
Alternative splicing with translation of part of an intron generates a T47 isoform, which misses the
nonsense mutation found in T48. Most of the variants of NLRP1 and CARD8 are poorly characterized.
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In contrast to the above-mentioned inflammasome sensors, NLRP1 has a FIIND. This domain
possesses protease activity needed for self-cleavage of NLRP1 between phenylalanine 1212 and serine
1213 in the SF/S motif of the FIIND [48]. F1212 and S1213 are strictly required for NLRP1 activation, as
well as the histidine residue H1186. Most likely, after deprotonation of S1213 supported by H1186
(and possibly by an unknown acidic amino acid acting as proton acceptor for H1186), S1213 represents
nucleophile attacking the C of the C-N bond between F1212 and S1213. Binding the hydrophobic side
chain of F1212 in a pocket of the FIIND would then position the backbone in a conformation suitable for a
nucleophilic attack by S1213 [48]. Therefore, the self-cleaving protease activity of FIIND might be based
on a classical catalytic triad commonly found in hydrolases, such as proteases [49]. NLRP1 self-cleavage
is necessary but not sufficient for NLRP1 activation [41,48,50,51]. The FIIND consist of the two domains
ZU5 (for ZO-1 and UNC5) and UPA (UNC5, PIDD and Ankyrins), which are present in other proteins
such as PIDD1 (p53-induced protein with a death domain protein 1) or CARD8 (Figure 1b) [50].
Interestingly, PIDD1 undergoes self-processing via a HF/S motif between ZU5 and UPA and is able
to induce NF-κB activation or caspase-2-dependent apoptosis [52]. After processing, ZU5 and UPA
further interact and hold both domains bound to each other by non-covalent interactions [50,53,54].
Further insight into the mechanisms underlying NLRP1 activation comes from murine studies.
In contrast to humans, mice express several NLRP1 alleles and particularly NLRP1b confers
susceptibility to infection by Bacillus anthracis [40,55]. Lethal factor (LF) is a metalloproteinase and part
of B. anthracis’ lethal toxin. LF is able to cleave and inactivate mitogen-activated protein kinases of the
host cells, thereby inhibiting the host defense system. Additionally, LF does also cleave murine NLRP1b
in the aminoterminus causing its activation [56,57]. Although human NLRP1 is not cleaved and
activated by LF, an engineered proteolytic cleavage event in the aminoterminus induces also human
NLRP1 activation [58]. Surprisingly, activation of human and murine NLRP1 is strictly dependent
on proteasomal activity demonstrating that proteolytic degradation is an essential step in NLRP1
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activation [53,59–62]. This because after auto-proteolytic activation of NLRP1b, the carboxyterminal
effector domain is inhibited by interaction with the aminoterminal NLRP1b fragment. After LF-induced
cleavage of the aminoterminal part, the newly generated aminoterminus of NLRP1b is targeted by the
N-end rule pathway, ubiquitinated and degraded by the proteasome [53,54,63,64]. After this “functional
degradation” of the inhibitory aminoterminal fragment, the liberated carboxyterminal effector domain
of NLRP1b induces ASC speck formation and activation of caspase-1 [53,54]. The intracellular bacterium
Shigella flexneri activates several types of inflammasomes [65], including NLRP1b [66,67]. Interestingly,
S. flexneri expresses an E3 ubiquitin ligase that ubiquitinates NLRP1b and causes its activation
independently of the N-end rule pathway but dependent on the proteasome [54]. In conclusion,
self-activation in the FIIND is a prerequisite for NLRP1 activation. Then, the carboxyterminal effector
domain remains in an inhibited state due to its interaction with the aminoterminal NLRP1 fragment,
until the latter is ubiquitinated and degraded by the proteasome (Figure 2a). One can expect that human
NLRP1 is activated in a similar way as murine NLRP1b. Still, all the players and, most importantly,
the involved E3 ubiquitin ligases remain to be identified. In contrast to all known inflammasomes







Figure 2. Mechanisms of NLRP1 and CARD8 activation. (a) NLRP1 activation is initiated by
self-processing in the FIIND. However, the aminoterminal fragment inhibits the carboxyterminal
effector protein containing the CARD by a non-covalent interaction. Upon ubiquitination of the
aminoterminal inhibitory fragment by unknown ubiquitin ligases, the latter is degraded by the
proteasome. The liberated effector fragment induces ASC speck formation, followed by caspase-1
activation and in turn processing of proIL-1 and -18 and gasdermin D (GSDMD). Secretion of the
cytokines induces inflammation supported by GSDMD-induced pyroptosis. (b) Activation of CARD8
is poorly understood. Most likely, self-processing induces direct activation of caspase-1 without
participation of ASC. In contrast to NLRP1, CARD8-induced caspase-1 activation causes mainly
pyroptosis by GSDMD cleavage rather than processing of proIL-1 and -18.
4. Talabostat and CARD8
In addition to B. anthracis and S. flexneri, murine NLRP1b is also activated by the pathogens Listeria
monocytogenes [67] and Toxoplasma gondii [68] as well as by the anti-cancer drug talabostat (Val-boroPro,
PT-100) [51,69]. Talabostat inhibits members of the dipeptidyl peptidase (DPP) family, including DPP8
and DPP9, which are supposed to be involved in NLRP1b activation [69], but also quiescent cell
proline dipeptidase (QPP) and FAP (fibroblast activating protein) [70]. The molecular mechanisms
underlying caspase-1 activation by talabostat are poorly characterized but it is believed that a substrate
of DPP8/DPP9 is involved in NLRP1b activation [69,71]. For talabostat-induced NLRP1b activation,
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FIIND processing is a prerequisite and the proteasome pathway is required [51,72]. Interestingly,
talabostat induces mainly pyroptosis in an NLRP1b-dependent but ASC-independent manner and
secretion of very low levels of mature IL-1β (if at all) [51,69,71,73]. In general, ASC-independent
inflammasome activation is believed to induce mainly pyroptosis without major processing of
proIL-1β [74,75]. Similarly, talabostat is only a very weak inducer of mature IL-1β secretion in human
PBMCs and human THP-1 cells [69,71]. Surprisingly, induction of pyroptosis in THP-1 cells and other
AML (acute myeloid leukemia) cells by talabostat is mediated by CARD8 rather than by NLRP1,
demonstrating that CARD8 is also able to form a type of inflammasome (Figure 2b) [64,76].
CARD8 shares with NLRP1 not only the FIIND but also the carboxyterminal CARD and the
self-cleavage at the SF/S motif (Figure 1b) [50,76]. CARD8 was originally identified as TUCAN
(tumor-up-regulated CARD-containing antagonist of caspase nine), as it interacts with caspase-9 and
inhibits Apaf1-dependent apoptosis [77], and as CARDINAL (CARD inhibitor of NF-κB-activating
ligands) that inhibits NF-κB activation [78]. In contrast, it was also reported that CARD8 induces
apoptosis and interacts with caspase-1 regulating its activation [79]. Splicing of CARD8 leads to several
variants (Figure 1b), which might have specific properties and functions. CARD8 was first described
as a 49 kDa protein (T48 isoform) lacking exons 1-3 and only later the full-length 60 kDa isoform was
described [80]. The 55 kDa isoform (T54) was shown to inhibit caspase-8 and -9 and it is specifically
associated with cancer cells [81]. Interestingly, CARD8 also takes part in the regulation of the NLRP3
inflammasome [12]. It directly interacts with NLRP3 and dampens activation of the inflammasome
sensor, which is relevant for different inflammatory diseases [82–84]. CAPS (cryopyrin-associated
periodic syndrome) is an autoinflammatory disease characterized by recurrent systemic inflammation
and caused by mutations in the NLRP3 gene [85]. Mutated NLRP3 in patients suffering from CAPS
cannot interact with CARD8 which in turn cannot inhibit NLRP3, thus causing increased production
of mature IL-1β [84]. PFAPA (periodic fever with aphthous stomatitis, pharyngitis, and cervical
adenitis) is a quite common autoinflammatory condition, affecting children. These children express
loss-of-function variants of CARD8 lacking the FIIND and CARD domains, hence unable to bind and
inhibit NLRP3 [83]. Furthermore, a CARD8 missense mutant defective in binding of NLRP3 was
identified in members of a family suffering from Crohn’s Disease (CD) [82]. Peripheral monocytes of
these patients secrete increased levels of IL-1β upon NLRP3 activation and the patients respond to
IL-1β inhibitors. Interestingly, the identified mutation is dominant-negative [82]. CARD8 is also linked
to CD due to its interaction and negative regulation of NOD2 (nucleotide-binding oligomerization
domain-containing protein 2) [86].
Although talabostat induces CARD8-dependent pyroptosis in human AML cells, such as THP-1
cells, and NLRP1b-dependent pyroptosis in murine immune cells [51,76], human keratinocytes treated
with the drug secrete very high levels of mature IL-1β [71]. Although human primary keratinocytes
(HPKs) express also high levels of CARD8 (Fenini, unpublished), talabostat-induced IL-1β secretion
requires expression of NLRP1 and ASC [71] (Fenini, unpublished). It is not yet understood why NLRP1
senses talabostat in human keratinocytes, whereas the drug activates CARD8 in THP-1 cells, as both
cell types express NLRP1 and CARD8.
5. The NLRP1 Inflammasome in Human Keratinocytes
In 2001, NLRP1 was identified as a novel Ced-4 family member and termed DEFCAP (Death
Effector Filament-forming Ced-4-like Apoptosis Protein) [87] or NAC (nucleotide-binding domain
and CARD) [88]. The 166 kDa protein plays a role in the induction of apoptosis and is expressed as a
long (DEFCAP-L) and active variant and as a 44 amino acid shorter (DEFCAP-S) and inactive variant
(Figure 1a) [87]. DEFCAP-S lacks exon 14 of the NLRP1 gene, is ubiquitously expressed and defective
in caspase-1 activation [48]. The function of DEFCAP-S/NLRP1∆ex14 is not known. Roles of NLRP1 in
apoptosis were later confirmed. An interaction of the sonic hedgehog (SHH) receptor Patched (Ptc)
with DRAL/FHL2 (down-regulated in rhabdomyosarcomas LIM-domain protein/Four-and-a-half LIM
protein 2) and NLRP1 or CARD8 [89] induces caspase-9-dependent apoptosis [90]. Furthermore, in the
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absence of caspase-1, NLRP1 can induce apoptosis requiring expression of ASC and caspase-8 [91].
NLRP1 is broadly expressed but at particularly high levels by neurons [92] and, interestingly, by
differentiated epithelial cells, such as epidermal keratinocytes [88].
In addition to NLRP1, human primary keratinocytes (HPKs) express other inflammasome
components such as ASC and caspase-1, as well as proIL-1β and -18 [93]. Most importantly, UVB
radiation induces inflammasome activation in HPKs [93] and it is believed that this pathway underlies
the induction of sunburn in humans [94]. UV radiation represents a major challenge and stressor for
the skin and particularly for epidermal keratinocytes, which absorb the majority of UVB, whereas
UVA is able to penetrate deeper into the skin. UVB does not only induce sunburn but is also an
important inducer of skin cancer, the most frequent type of human malignancy [95,96]. UVB represents
a classical inducer of apoptosis, particularly in keratinocytes, and this cell death pathway antagonizes
the development of skin cancer [97,98]. Interestingly, caspase-1 is also a regulator of UVB-induced
apoptosis of HPKs independently on inflammasome activation [39,99] and a role of caspase-1 in
apoptosis is also discussed in other cell types [100–103]. So far, apart from Toxoplasma gondii in
monocytic cells [104], UVB radiation represents the only known physiological activator of NLRP1
in human cells. By siRNA/shRNA approaches, NLRP1 but also NLRP3 were identified to sense
UVB in human keratinocytes [93,105]. However, NLRP1 is considered the principal inflammasome
sensor in human keratinocytes in vitro and in the skin [43]. Most likely, siRNA causes a kind of
priming of keratinocytes for NLRP3 expression, as a study based on knockout HPKs generated by
the CRISPR/Cas9 approach revealed that NLRP1 rather than NLRP3 is the UVB sensor in HPKs [106].
Moreover, the microbial toxin nigericin, a classical inducer of the NLRP3 inflammasome, is also
sensed by NLRP1 in HPKs [106,107]. The molecular mechanisms underlying UVB-induced NLRP1
inflammasome activation are poorly understood but an increase in intracellular Ca2+ and reactive
oxygen species (ROS) are likely contributing factors [93,99].
Upon treatment of HPKs with IFNγ or TNFα (priming), expression of other inflammasome
sensors is induced [106,108]. Next to NLRP1, the AIM2 inflammasome also has relevant functions
in human keratinocytes, since it senses infection by Herpes simplex virus (HSV) [109]. Moreover,
the AIM2 inflammasome plays an important role in psoriasis, a common inflammatory skin disease, as
cytosolic DNA triggers AIM2 inflammasome activation in HPKs and in lesion of patients suffering
from the disease [110].
Although caspase-1 expression is required for the induction of UVB-induced skin inflammation in
mice [93], UVB irradiation of murine keratinocytes neither in vitro nor in vivo induces inflammasome
activation in keratinocytes [111]. Moreover, in contrast to human keratinocytes, murine keratinocytes
do not express significant amounts of proIL-1β and NLRP1 [111]. Therefore, it is likely that an
unidentified (immune) cell type in murine skin acts as the IL-1β producer upon UVB-irradiation,
a duty that might be fulfilled by keratinocytes in human skin. These results demonstrate important
differences between human and murine epidermis and keratinocytes. These differences in response
to UVB and activation of NLRP1 suggest that mice represent a model with limited relevance for
NLRP1-dependent UVB responses in human skin, such as sunburn and UVB-induced skin cancer
development (see below). In contrast, there is evidence that AIM2, caspase-1 and proIL-1β are required
for inflammatory memory of murine epithelial stem cells, sensitizing them for more efficient repair
after tissue injury [112]. It should be considered that results obtained with keratinocytes in vitro may
not be necessarily representative for keratinocytes in vivo. It might be that keratinocytes in culture and
in vivo are in differently primed states concerning inflammasome activation. In conclusion, in contrast
to murine keratinocytes, there is convincing evidence for expression and activation of the NLRP1
inflammasome in human keratinocytes.
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6. The NLRP1 Inflammasome in Human Skin
Mutations of NLRP1 have been described in patients who suffer from different inflammatory
diseases with a skin phenotype, demonstrating that NLRP1 plays a particularly important role in the





Figure 3. NLRP1 activation in human keratinocytes. In human keratinocytes, NLRP1 is activated
by UVB radiation, nigericin, or talabostat. Toxoplasma gondii activates NLRP1 in monocytes.
Via caspase-1 activation, this causes processing and secretion of proIL-1β and -18. IL-1β and -18 induce
hyperproliferation of epidermal keratinocytes by autocrine and paracrine signaling and inflammation.
Chronic NLRP1-dependent inflammation in the skin predisposes patients to the development of SCCs,
a type of keratinocyte-derived skin cancer [43,71,106,113].
MSPC (multiple self-healing palmoplantar carcinoma) and FKLC (familial keratosis lichenoides
chronica) are two rare monogenic inflammatory skin diseases, which are caused by gain-of-function
(GoF) mutations of NLRP1 [43]. The mutations occur in the aminoterminal pyrin domain of NLRP1
(MSPC) or in the LRRs (FKLC). NLRP1 is the only inflammasome sensor detectable in human skin,
expressed by fibroblasts and keratinocytes [43]. Keratinocytes but not fibroblasts express major levels
of caspase-1, ASC, proIL-1β and proIL-18, suggesting that keratinocytes but not fibroblasts express a
functional NLRP1 inflammasome [43,111]. Most importantly, immortalized keratinocytes expressing
the NLRP1 GoF mutants secreted more mature IL-1β than cells expressing wild type NLRP1 [43].
Furthermore, HPKs from MSPC and FKLC patients secreted more IL-1β and -18 than cells from
healthy individuals [43]. Although a formal proof is missing, these results strongly suggest that MSPC
and FKLC patients suffer from skin inflammation due to the expression of GoF mutants of NLRP1
in epidermal keratinocytes. Interestingly, patients suffering from CAPS, which is caused by GoF
mutations of NLRP3 (under normal conditions NLRP3 is not detectable in keratinocytes [43,106]),
do also suffer from—among other symptoms—a skin phenotype [114]. MSPC predisposes patients to
the development of SCCs (squamous cell carcinomas) [43], a major type of skin cancer, suggesting that
NLRP1-dependent skin inflammation supports the development of tumors [115–117]. In line with
this hypothesis is the observation that canakinumab, a monoclonal antibody targeting IL-1β, prevents
the development of lung cancer [118,119]. In contrast, inflammasomes might also be implicated
in the suppression of cancer development due to their roles in cancer cell death, repair processes,
and anti-cancer immunity [115–117]. The finding that expression of the NLRP1 inflammasome,
although GoF mutants of NLRP1 predispose for SCC development [43], is suppressed in SCC cell lines
and existing SCC tumors [113] supports a dual, paradoxical and cell type, stage- and/or time-specific
role of inflammasomes in (skin) cancer development.
Recently, a novel autoimmune-inflammatory disease termed NAIAD (NLRP1-associated
autoinflammation with arthritis and dyskeratosis) with a clear skin phenotype has been described. It is
caused by mutations of NLRP1 occurring either between the NACHT and LRRs or within the FIIND,
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close to the autoprocessing site [45]. The serum of patients contained higher levels of caspase-1, IL-18
and partially IL-1β, suggesting that the mutations cause increased NLRP1 activation.
Furthermore, several other SNPs of NLRP1 are associated with an increased risk for the
development of several diseases with partial involvement of the skin [40]. Vitiligo is a non-curable,
autoimmune-linked disease causing depigmentation of the skin, hair, and oral mucosa due to the
progressive loss of melanocytes [120]. Several different variants of the NLRP1 gene were found to be
associated with vitiligo [44,121–123]. The risk of contracting psoriasis is also associated with variants
of the NLRP1 gene [47,121]. Up to 2% of the population suffer from this condition, an inflammatory
and hyper-proliferative skin disease, which can also affect other organs [124]. Other conditions
with, but also without, an involvement of skin are linked to NLRP1. These include systemic lupus
erythematosus [121,125], leprosy [126], juvenile-onset recurrent respiratory papillomatosis (JRRP) [46],
and several others [40,127].
In conclusion, NLRP1 is the only inflammasome sensor expressed by keratinocytes in vitro and
in vivo in the skin under normal and homeostatic conditions [43]. Furthermore, these cells express all
the components required for NLRP1 inflammasome activation and the induction of inflammation [43,93].
As UVB [93] and talabostat [71] activate the NLRP1 inflammasome in human keratinocytes, it is likely
that GoF mutations of NLRP1 cause skin inflammation via hyperactivation of the inflammasome in
epidermal keratinocytes. This demonstrates a particularly important role of NLRP1 in keratinocytes
and in the skin.
7. Outlook and Open Questions
Pharmacological targeting of NLRP1 activation represents an attractive strategy for treatment
of the many patients suffering from NLRP1-dependent skin conditions. Due to its accessibility, the
skin is predestined for topical application of small hydrophobic molecules able to penetrate into the
tissue and into epidermal keratinocytes as well as skin-resident immune cells. Moreover, as patients
with GoF mutations of NLRP1 have mainly a skin phenotype, systemic treatment of patients suffering
from NLRP1-dependent skin conditions with NLRP1 targeting molecules also might perhaps represent
a possible approach with tolerable side-effects. Inhibition of NLRP1 might be effective for patients
suffering from inflammatory skin conditions such as vitiligo or psoriasis. Furthermore, as the NLRP1
pathway is silenced in skin cancer [113], pharmacological activation of NLRP1 in affected skin lesions,
for example by talabostat, might represent a successful approach for the treatment of skin cancer
patients. The immune system plays a particularly important role in the development and treatment of
skin cancer [96], and its activation, for example by imiquimod, is a successful strategy to combat skin
cancer [128].
Several open points revolve around the molecular mechanisms underlying talabostat-induced
inflammasome activation and particularly the cell type-specific consequences. What are the DPP8/9
substrates that regulate activation of human NLRP1, CARD8, and murine NLRP1b? Why does NLRP1
sense talabostat in keratinocytes, whereas CARD8 expression is required for caspase-1 activation in
AML cells, although both cell types express NLRP1 and CARD8? Talabostat-induced CARD8 and
downstream caspase-1 activation (and murine NLRP1b activation [51,69]) causes only pyroptosis [76],
whereas talabostat-induced NLRP1 activation in human keratinocytes induces very effective processing
of proIL-1β/-18 and secretion of the mature cytokines [71]. What determines the substrate specificity of
caspase-1? Are ASC specks required for caspase-1-induced processing of proIL-1β and -18 but not for
activation of gasdermin D [74,75]?
CARD8 is not only able to cause caspase-1 activation (in talabostat-treated AML cells) but can
also inhibit NLRP3 upon direct interaction [82–84]. The active carboxyterminal effector domain of
NLRP1 shares significant homology with the carboxyterminal fragment of CARD8. Can NLRP1 also
inhibit NLRP3 activation? Is there a crosstalk between different inflammasome sensors? The NLRP1
variant lacking exon 14 (DEFCAP-S) cannot cause caspase-1 activation and is widely expressed [87].
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What is its physiological role? Interestingly, a viral homologue of NLRP1 expressed by Kaposi’s
sarcoma-associated herpesvirus (KSHV) binds and inhibits NLRP1, NLRP3, and NOD2 [129].
Since its discovery almost 20 years ago, we learned a lot about the molecular mechanisms
underlying upstream and downstream pathways of NLRP1 and its physiologic roles in humans and
mice. NLRP1 activation is regulated in a very complex manner, sharing certain aspects with other
inflammasome sensors. In addition, NLRP1 activation is characterized by very specific features,
such as proteolytic self-activation and functional degradation. In the near future, we can expect a
better understanding of the mechanisms governing NLRP1 activation and its species-specific roles in
the skin and beyond.
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